Iovance Biotherapeutics (IOVA) Capital Expenditures (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Capital Expenditures of $6.6 million for Q1 2026, up 6.39% year-over-year from $6.2 million in Q1 2025, and down 29.1% quarter-over-quarter from $9.3 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Capital Expenditures (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Capital Expenditures for 14 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 6.39% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $34.2 million (up 161.14% YoY), while the FY2025 annual figure was $33.8 million, up 205.68% from the prior year.
- Capital Expenditures retreated to $6.6 million in Q1 2026 per IOVA's latest filing, from $9.3 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $11.4 million in Q1 2022 and bottomed at $442000.0 in Q2 2024.
- Historically, Capital Expenditures has averaged $5.5 million across 5 years, with a median of $4.6 million in 2022.
- Annual changes were most pronounced in 2024 — Capital Expenditures plunged 95.36% — and 2025, when it surged 1588.01%.
- Iovance Biotherapeutics' Capital Expenditures stood at $3.0 million in 2022, then grew by 16.78% to $3.5 million in 2023, then gained by 18.11% to $4.2 million in 2024, then jumped by 123.61% to $9.3 million in 2025, then fell by 29.1% to $6.6 million in 2026.
- Business Quant data shows IOVA's Capital Expenditures at $6.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 5.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.44 Mn |
| Jun 30, 2026 | 5.44 Mn |
| Mar 31, 2026 | 6.61 Mn |
| Mar 31, 2026 | 6.61 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Sep 30, 2025 | 10.84 Mn |
| Sep 30, 2025 | 10.84 Mn |
| Jun 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 7.46 Mn |
| Mar 31, 2025 | 6.21 Mn |
| Mar 31, 2025 | 6.21 Mn |
| Dec 31, 2024 | 4.17 Mn |
| Dec 31, 2024 | 4.17 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 442,000.00 |
| Jun 30, 2024 | 442,000.00 |
| Mar 31, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.17 Mn |